Exclusive US rights acquired by CLS | March 5, 2018 (WAYNE, PA) – Cutanea Life Sciences, Inc. has acquired the exclusive US commercialization rights for Xepi™ (ozenoxacin) Cream, 1% from Medimetriks Pharmaceuticals, Inc. Xepi™ is licensed from Spanish drug maker FERRER INTERNACIONAL, S.A., who developed the patented topical impetigo treatment that was recently approved for use in the U.S. by the Food and Drug Administration.
